Collectively, these finding suggested that the interaction between osteosarcoma cells and platelets, via thrombin and TGF-β, results in a continuous cycle, and that anti-TGF-β or anti-Smad3 therapy could be a promising tool for disease treatment (Saito et al., 2018). The gene discussed is SMAD3; the disease is osteosarcoma.